Related Experiment Video
Updated: Oct 24, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
Mucosal vaccine development for respiratory viral infections
Yifan Lin1, Zhenxiang Hu2, Yang-Xin Fu1
1Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China.
Abstract:
Mucosal vaccines have risen to prominence in the corona virus disease 2019 (COVID-19) pandemic due to their ability to elicit both local antibody and tissue-resident T cell responses, affording a dual-layered defense against infection and transmission at respiratory entry sites. While intramuscular vaccines predominantly focus on systemic immunity, mucosal vaccines offer a more nuanced, site-specific approach. However, the field faces a dearth of mucosal vaccine options for respiratory diseases, starkly contrasting to the extensive array of well-characterized injectable vaccines. The unique features of mucosal surfaces necessitate specialized adjuvants and delivery systems, adding complexity to adapting injectable vaccine technologies for mucosal applications. Here, we review the recent insights into the specificities of respiratory mucosal immunology that provide a foundation for future innovations besides the emerging vaccine platforms, newly discovered adjuvants, and vaccine delivery systems, which may open promising avenues for developing mucosal vaccines targeting respiratory pathogens.
Related Concept Videos
Respiratory Syncytial Virus Disease
Viral Structure
Microorganisms in Medicine and Therapeutics
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Microbiota of the Respiratory Tract
Vaccines

